Thyrocare Technologies（THYROCARE）株式概要Thyrocare Technologies Limitedは、インドの患者、研究所、病院に診断検査サービスを提供している。 詳細THYROCARE ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長5/6過去の実績5/6財務の健全性5/6配当金4/6報酬収益は年間20.14%増加すると予測されています 過去1年間で収益は65.9%増加しました リスク分析1.5%の配当は利益で十分にカバーされていない すべてのリスクチェックを見るTHYROCARE Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW472,568 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA472,568 investors already sharing narrativesYour Fair Value₹Current Price₹624.056.6% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture018b2016201920222025202620282031Revenue ₹18.3bEarnings ₹3.7bAdvancedSet Fair ValueView all narrativesThyrocare Technologies Limited 競合他社Metropolis HealthcareSymbol: NSEI:METROPOLISMarket cap: ₹113.1bVijaya Diagnostic CentreSymbol: NSEI:VIJAYAMarket cap: ₹151.7bNephrocare Health ServicesSymbol: NSEI:NEPHROPLUSMarket cap: ₹69.9bDr. Lal PathLabsSymbol: NSEI:LALPATHLABMarket cap: ₹320.1b価格と性能株価の高値、安値、推移の概要Thyrocare Technologies過去の株価現在の株価₹624.0552週高値₹662.0052週安値₹342.55ベータ0.461ヶ月の変化17.69%3ヶ月変化35.03%1年変化35.30%3年間の変化251.18%5年間の変化45.33%IPOからの変化210.68%最新ニュース分析記事 • Jul 26Thyrocare Technologies Limited Just Missed Earnings - But Analysts Have Updated Their ModelsIt's been a good week for Thyrocare Technologies Limited ( NSE:THYROCARE ) shareholders, because the company has just...Price Target Changed • Jul 25Price target increased by 7.6% to ₹649Up from ₹603, the current price target is an average from 5 analysts. New target price is 15% above last closing price of ₹564. Stock is up 29% over the past year. The company is forecast to post earnings per share of ₹13.13 for next year compared to ₹10.24 last year.Reported Earnings • Jul 24First quarter 2027 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2027 results: EPS: ₹3.23 (up from ₹2.45 in 1Q 2026). Revenue: ₹2.44b (up 27% from 1Q 2026). Net income: ₹521.9m (up 34% from 1Q 2026). Profit margin: 21% (up from 20% in 1Q 2026). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 5.2%. Earnings per share (EPS) missed analyst estimates by 41%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 38% per year whereas the company’s share price has increased by 43% per year.お知らせ • Jul 16Thyrocare Technologies Limited to Report Q1, 2027 Results on Jul 23, 2026Thyrocare Technologies Limited announced that they will report Q1, 2027 results on Jul 23, 2026お知らせ • Jul 01+ 1 more updateThyrocare Technologies Limited Approves Board Appointments, Effective May 8, 2026Thyrocare Technologies Limited at its annual general meeting held on June 30, 2026 approved the appointment of Mr. Gaurav Verma as Director (Non-Executive and Non-Independent), Mr. Uday Patel Kadam as Director (Non-Executive and Non-Independent of the Company with effect from May 8, 2026.Upcoming Dividend • Jun 16Upcoming dividend of ₹7.00 per shareEligible shareholders must have bought the stock before 23 June 2026. Payment date: 29 July 2026. Payout ratio and cash payout ratio are on the higher end at 91% and 77% respectively. Trailing yield: 1.8%. Within top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.3%).最新情報をもっと見るRecent updates分析記事 • Jul 26Thyrocare Technologies Limited Just Missed Earnings - But Analysts Have Updated Their ModelsIt's been a good week for Thyrocare Technologies Limited ( NSE:THYROCARE ) shareholders, because the company has just...Price Target Changed • Jul 25Price target increased by 7.6% to ₹649Up from ₹603, the current price target is an average from 5 analysts. New target price is 15% above last closing price of ₹564. Stock is up 29% over the past year. The company is forecast to post earnings per share of ₹13.13 for next year compared to ₹10.24 last year.Reported Earnings • Jul 24First quarter 2027 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2027 results: EPS: ₹3.23 (up from ₹2.45 in 1Q 2026). Revenue: ₹2.44b (up 27% from 1Q 2026). Net income: ₹521.9m (up 34% from 1Q 2026). Profit margin: 21% (up from 20% in 1Q 2026). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 5.2%. Earnings per share (EPS) missed analyst estimates by 41%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 38% per year whereas the company’s share price has increased by 43% per year.お知らせ • Jul 16Thyrocare Technologies Limited to Report Q1, 2027 Results on Jul 23, 2026Thyrocare Technologies Limited announced that they will report Q1, 2027 results on Jul 23, 2026お知らせ • Jul 01+ 1 more updateThyrocare Technologies Limited Approves Board Appointments, Effective May 8, 2026Thyrocare Technologies Limited at its annual general meeting held on June 30, 2026 approved the appointment of Mr. Gaurav Verma as Director (Non-Executive and Non-Independent), Mr. Uday Patel Kadam as Director (Non-Executive and Non-Independent of the Company with effect from May 8, 2026.Upcoming Dividend • Jun 16Upcoming dividend of ₹7.00 per shareEligible shareholders must have bought the stock before 23 June 2026. Payment date: 29 July 2026. Payout ratio and cash payout ratio are on the higher end at 91% and 77% respectively. Trailing yield: 1.8%. Within top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.3%).Reported Earnings • Jun 09Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹10.27 (up from ₹5.76 in FY 2025). Revenue: ₹8.29b (up 21% from FY 2025). Net income: ₹1.63b (up 78% from FY 2025). Profit margin: 20% (up from 13% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.4%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jun 05Thyrocare Technologies Limited, Annual General Meeting, Jun 30, 2026Thyrocare Technologies Limited, Annual General Meeting, Jun 30, 2026, at 11:00 Indian Standard Time. Location: d-37/3. ttc industrial area, midc, turbhe, navi mumbai - 400703., navi mumba IndiaNew Risk • May 14New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 91% Cash payout ratio: 116% Dividend yield: 3.0% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • May 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹471, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 40x in the Healthcare industry in India. Total returns to shareholders of 220% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹282 per share.お知らせ • Apr 29Thyrocare Technologies Limited to Report Q4, 2026 Results on May 07, 2026Thyrocare Technologies Limited announced that they will report Q4, 2026 results on May 07, 2026Reported Earnings • Jan 29Third quarter 2026 earnings: EPS and revenues miss analyst expectationsThird quarter 2026 results: EPS: ₹1.82 (up from ₹1.19 in 3Q 2025). Revenue: ₹1.96b (up 18% from 3Q 2025). Net income: ₹290.1m (up 52% from 3Q 2025). Profit margin: 15% (up from 12% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) also missed analyst estimates by 75%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 20Thyrocare Technologies Limited to Report Q3, 2026 Results on Jan 28, 2026Thyrocare Technologies Limited announced that they will report Q3, 2026 results on Jan 28, 2026お知らせ • Jan 05Thyrocare Technologies Limited Appoints Rajdeep Panwar as Chief Commercial Officer, Effective January 5, 2026Thyrocare Technologies Limited approved the appointment of Mr. Rajdeep Panwar as Chief Commercial Officer of the Company, categorised as Senior Management Personnel, with effect from January 5, 2026. Mr. Rajdeep Panwar is a senior healthcare and diagnostics industry professional with over 21 years of experience, having led large-scale diagnostic networks, laboratory operations and commercial functions across reputed healthcare organisations. He most recently served as Director – GHL Pharma & Diagnostics Limited (Medanta Labs), where he led the establishment and expansion of laboratory and pharmacy business verticals across North India. His prior experience includes leadership roles at Apollo Diagnostics, Dr. Lal PathLabs, Ortho Clinical Diagnostics (Johnson & Johnson Group), Quest Diagnostics India Private Limited, Sitaram Bhartia Institute of Science & Research and Pathnet India Private Limited. Mr. Panwar has extensive experience in P&L management, laboratory network expansion, business launches, digital diagnostics initiatives, NABL/CAP accreditation, LIMS integration and large-scale team leadership, and has played a key role in scaling diagnostic operations across metro and non-metro markets. He holds an M.Sc. in Biochemistry, B.Sc. in Medical Laboratory Technology, a Diploma in Medical Laboratory Technology, and is trained as an Internal Auditor for NABL ISO 15189.分析記事 • Dec 17Is Now The Time To Put Thyrocare Technologies (NSE:THYROCARE) On Your Watchlist?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Valuation Update With 7 Day Price Move • Nov 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹1,564, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 44x in the Healthcare industry in India. Total returns to shareholders of 173% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹818 per share.分析記事 • Nov 17After Leaping 26% Thyrocare Technologies Limited (NSE:THYROCARE) Shares Are Not Flying Under The RadarThyrocare Technologies Limited ( NSE:THYROCARE ) shares have had a really impressive month, gaining 26% after a shaky...Upcoming Dividend • Oct 17Upcoming dividend of ₹7.00 per shareEligible shareholders must have bought the stock before 24 October 2025. Payment date: 13 November 2025. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 1.7%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.3%).Reported Earnings • Oct 15Second quarter 2026 earnings released: EPS: ₹9.05 (vs ₹4.99 in 2Q 2025)Second quarter 2026 results: EPS: ₹9.05 (up from ₹4.99 in 2Q 2025). Revenue: ₹2.20b (up 24% from 2Q 2025). Net income: ₹479.9m (up 80% from 2Q 2025). Profit margin: 22% (up from 15% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Oct 11Thyrocare Technologies (NSE:THYROCARE) Is Reinvesting To Multiply In ValueTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...お知らせ • Oct 06Thyrocare Technologies Limited to Report Q2, 2026 Results on Oct 14, 2025Thyrocare Technologies Limited announced that they will report Q2, 2026 results at 12:15 PM, Indian Standard Time on Oct 14, 2025分析記事 • Aug 23Thyrocare Technologies (NSE:THYROCARE) Has A Rock Solid Balance SheetHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Board Change • Aug 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Additional Non-Executive & Non-Independent Director Alok Jagnani was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.分析記事 • Jul 25Thyrocare Technologies Limited's (NSE:THYROCARE) Shares Climb 40% But Its Business Is Yet to Catch UpThyrocare Technologies Limited ( NSE:THYROCARE ) shares have continued their recent momentum with a 40% gain in the...Upcoming Dividend • Jul 18Upcoming dividend of ₹21.00 per shareEligible shareholders must have bought the stock before 25 July 2025. Payment date: 30 August 2025. The company is paying out more than 100% of its profits and is paying out 76% of its cash flow. Trailing yield: 1.8%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.3%).お知らせ • Jul 16Thyrocare Technologies Limited to Report Q1, 2026 Results on Jul 23, 2025Thyrocare Technologies Limited announced that they will report Q1, 2026 results on Jul 23, 2025New Risk • Jul 14New major risk - Revenue and earnings growthEarnings have declined by 8.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.3% per year over the past 5 years. Minor Risk Dividend is not well covered by earnings (122% payout ratio).Price Target Changed • Jul 11Price target increased by 19% to ₹1,125Up from ₹943, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of ₹1,085. Stock is up 70% over the past year. The company is forecast to post earnings per share of ₹20.80 for next year compared to ₹17.28 last year.Reported Earnings • Jul 08Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹17.13 (up from ₹13.37 in FY 2024). Revenue: ₹6.87b (up 20% from FY 2024). Net income: ₹915.1m (up 29% from FY 2024). Profit margin: 13% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 27%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.お知らせ • Jul 07Thyrocare Technologies Limited, Annual General Meeting, Jul 31, 2025Thyrocare Technologies Limited, Annual General Meeting, Jul 31, 2025, at 10:30 Indian Standard Time. Location: d-37/3. ttc industrial area, midc, turbhe, navi mumbai - 400703., navi mumba India分析記事 • May 02Thyrocare Technologies' (NSE:THYROCARE) Solid Earnings Have Been Accounted For ConservativelyInvestors signalled that they were pleased with Thyrocare Technologies Limited's ( NSE:THYROCARE ) most recent earnings...分析記事 • Apr 26After Leaping 26% Thyrocare Technologies Limited (NSE:THYROCARE) Shares Are Not Flying Under The RadarThyrocare Technologies Limited ( NSE:THYROCARE ) shareholders would be excited to see that the share price has had a...Reported Earnings • Apr 24Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹17.13 (up from ₹13.37 in FY 2024). Revenue: ₹7.02b (up 23% from FY 2024). Net income: ₹915.1m (up 29% from FY 2024). Profit margin: 13% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 27%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.お知らせ • Apr 23Thyrocare Technologies Limited Recommends Final Dividend for the Financial Year 2024-25Thyrocare Technologies Limited at its board meeting held on April 23, 2025, recommended Final Dividend of INR 21 per equity share for the financial year 2024-25 subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. The Dividend, if declared by shareholders, shall be paid within 30 days from the date of the AGM.分析記事 • Apr 23The Returns On Capital At Thyrocare Technologies (NSE:THYROCARE) Don't Inspire ConfidenceIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...お知らせ • Apr 15Thyrocare Technologies Limited to Report Q4, 2025 Results on Apr 23, 2025Thyrocare Technologies Limited announced that they will report Q4, 2025 results on Apr 23, 2025New Risk • Apr 08New major risk - Revenue and earnings growthEarnings have declined by 8.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.0% per year over the past 5 years. Minor Risk Dividend is not well covered by earnings (135% payout ratio).分析記事 • Jan 28Thyrocare Technologies Limited Just Missed Earnings - But Analysts Have Updated Their ModelsThyrocare Technologies Limited ( NSE:THYROCARE ) shareholders are probably feeling a little disappointed, since its...Reported Earnings • Jan 24Third quarter 2025 earnings: EPS misses analyst expectationsThird quarter 2025 results: EPS: ₹3.58 (up from ₹2.78 in 3Q 2024). Revenue: ₹1.70b (up 26% from 3Q 2024). Net income: ₹191.1m (up 25% from 3Q 2024). Profit margin: 11% (in line with 3Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 15%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.お知らせ • Jan 23Thyrocare Technologies Limited Announces Company Secretary and Compliance Officer Changes, Effect from January 31, 2025Thyrocare Technologies Limited announced that Mr. Ramjee Dorai, Company Secretary and Compliance Officer will retire from the services of the Company with effect from the close of business hours on January 31, 2025. announced the appointment of Mr. Brijesh Kumar as Company Secretary, Compliance Officer and Key Managerial Personnel of the Company with effect from January 31, 2025, to take over from Mr. Ramjee Dorai consequent on the latter's superannuation. Mr. Brijesh Kumar is a qualified Company Secretary, a law graduate, and holds an Honors degree in Commerce (B. Com Hons). He also possesses a diploma in e-Commerce and has over 12 years of experience in corporate secretarial and legal affairs. He has expertise in Securities and Capital Market Laws, Corporate Laws, FEMA, compliance management, and has handled mergers and acquisitions, share listings, fund- raising initiatives, ESOPs, joint ventures, and other critical corporate actions. Prior to joining Thyrocare Technologies Limited, he served as Head Company Secretary & Compliance Officer at Jubilant Industries Limited. Earlier he held key roles in the secretarial functions of Uno Minda Limited and AKM Global.お知らせ • Jan 16Thyrocare Technologies Limited to Report Q3, 2025 Results on Jan 23, 2025Thyrocare Technologies Limited announced that they will report Q3, 2025 results on Jan 23, 2025Valuation Update With 7 Day Price Move • Jan 13Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹824, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 48x in the Healthcare industry in India. Total loss to shareholders of 13% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹718 per share.Recent Insider Transactions • Nov 07MD, CEO & Chairman recently bought ₹1.1m worth of stockOn the 1st of November, Rahul Guha bought around 1k shares on-market at roughly ₹964 per share. This transaction amounted to 2.2% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Rahul's only on-market trade for the last 12 months.分析記事 • Oct 31Statutory Profit Doesn't Reflect How Good Thyrocare Technologies' (NSE:THYROCARE) Earnings AreThyrocare Technologies Limited ( NSE:THYROCARE ) just reported healthy earnings but the stock price didn't move much...Price Target Changed • Oct 24Price target increased by 9.1% to ₹903Up from ₹828, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of ₹915. Stock is up 74% over the past year. The company is forecast to post earnings per share of ₹18.60 for next year compared to ₹13.37 last year.Reported Earnings • Oct 24Second quarter 2025 earnings released: EPS: ₹4.99 (vs ₹3.84 in 2Q 2024)Second quarter 2025 results: EPS: ₹4.99 (up from ₹3.84 in 2Q 2024). Revenue: ₹1.77b (up 20% from 2Q 2024). Net income: ₹266.7m (up 31% from 2Q 2024). Profit margin: 15% (up from 14% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.Board Change • Oct 18High number of new directorsIndependent Director Nishant Shah was the last director to join the board, commencing their role in 2024.お知らせ • Oct 16Thyrocare Technologies Limited to Report Q2, 2025 Results on Oct 23, 2024Thyrocare Technologies Limited announced that they will report Q2, 2025 results on Oct 23, 2024Buy Or Sell Opportunity • Oct 16Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 38% to ₹890. The fair value is estimated to be ₹724, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Earnings per share has declined by 45%.Price Target Changed • Oct 12Price target increased by 8.5% to ₹828Up from ₹763, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of ₹829. Stock is up 45% over the past year. The company is forecast to post earnings per share of ₹18.20 for next year compared to ₹13.37 last year.お知らせ • Oct 11Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million.Thyrocare Technologies Limited (BSE:539871) entered into Business Transfer Agreement to acquire Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million on August 30, 2024. A cash consideration of INR 70 million will be paid by Thyrocare Technologies Limited. For the period ended March 31, 2024 Diagnostics and and pathological services business of Virnta Labs Limited had revenue of INR 296.67 million. Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million on October 11, 2024.お知らせ • Sep 19+ 1 more updateThyrocare Technologies Limited Announces Cessation of Mr. Neetin Shivajirao Desai as Independent Director as Well as Member of the Respective Committee(s) of the BoardThyrocare Technologies Limited announced that the second term as Independent Director of Mr. Neetin Shivajirao Desai will be over at the close of office hours of September 19, 2024, and consequently he will cease to be a Director as well as Member of the respective Committee(s) of the Board.Buy Or Sell Opportunity • Sep 03Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 44% to ₹869. The fair value is estimated to be ₹723, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Earnings per share has declined by 45%. Revenue is forecast to grow by 14% in a year. Earnings are forecast to grow by 35% in the next year.お知らせ • Aug 27Thyrocare Technologies Limited Approves Dividend for the Financial Year 2023-24Thyrocare Technologies Limited at its AGM held on August 23, 2024 approved to declare dividend of INR 18 per equity share of face value of INR 10 per each for the financial year 2023-24.お知らせ • Aug 21Thyrocare Technologies Limited Announces Cessation of Gopalkrishna Shivaram Hegde as Independent Director and as Member / Chairman of the Respective CommitteeThyrocare Technologies Limited announced that the second term as Independent Director of Mr. Gopalkrishna Shivaram Hegde will be over at the close of office hours of August 20, 2024, and consequently he will cease to be a Director as well as Member /Chairman of the respective Committee of the Board.Buy Or Sell Opportunity • Aug 13Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 33% to ₹867. The fair value is estimated to be ₹722, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Earnings per share has declined by 45%. Revenue is forecast to grow by 14% in a year. Earnings are forecast to grow by 35% in the next year.Upcoming Dividend • Aug 09Upcoming dividend of ₹18.00 per shareEligible shareholders must have bought the stock before 16 August 2024. Payment date: 22 September 2024. The company is paying out more than 100% of its profits and is paying out 90% of its cash flow. Trailing yield: 2.2%. Within top quartile of Indian dividend payers (1.1%). Higher than average of industry peers (0.3%).お知らせ • Aug 02Thyrocare Technologies Limited, Annual General Meeting, Aug 23, 2024Thyrocare Technologies Limited, Annual General Meeting, Aug 23, 2024, at 16:00 Indian Standard Time. Location: d-37/3. ttc industrial area, midc, turbhe, navi mumbai - 400703., navi mumba India分析記事 • Aug 01Thyrocare Technologies Limited (NSE:THYROCARE) Looks Just Right With A 26% Price JumpThe Thyrocare Technologies Limited ( NSE:THYROCARE ) share price has done very well over the last month, posting an...Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹776, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 45x in the Healthcare industry in India. Total loss to shareholders of 38% over the past three years.お知らせ • Jul 30Thyrocare Technologies Limited (BSE:539871) acquired Diagnostic and pathological services business of Polo Labs Private Limited for INR 42.6 million.Thyrocare Technologies Limited (BSE:539871) entered into business transfer agreement to acquire Diagnostic and pathological services business of Polo Labs Private Limited for INR 42.6 million on July 2, 2024. The transaction is expected to complete 60 business days from the execution date of the business transfer agreement . Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostic and pathological services business of Polo Labs Private Limited on July 29, 2024.分析記事 • Jul 26Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This YearShareholders will be ecstatic, with their stake up 20% over the past week following Thyrocare Technologies Limited 's...Buy Or Sell Opportunity • Jul 24Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 16% to ₹765. The fair value is estimated to be ₹623, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Earnings per share has declined by 45%. Revenue is forecast to grow by 13% in a year. Earnings are forecast to grow by 35% in the next year.Reported Earnings • Jul 24First quarter 2025 earnings released: EPS: ₹4.52 (vs ₹3.26 in 1Q 2024)First quarter 2025 results: EPS: ₹4.52 (up from ₹3.26 in 1Q 2024). Revenue: ₹1.61b (up 19% from 1Q 2024). Net income: ₹241.7m (up 40% from 1Q 2024). Profit margin: 15% (up from 13% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.お知らせ • Jul 17Thyrocare Technologies Limited to Report Q1, 2025 Results on Jul 23, 2024Thyrocare Technologies Limited announced that they will report Q1, 2025 results on Jul 23, 2024Buy Or Sell Opportunity • Jun 12Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 3.6% to ₹662. The fair value is estimated to be ₹539, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 40%. Revenue is forecast to grow by 32% in 2 years. Earnings are forecast to grow by 58% in the next 2 years.分析記事 • Jun 12A Look At The Fair Value Of Thyrocare Technologies Limited (NSE:THYROCARE)Key Insights Using the 2 Stage Free Cash Flow to Equity, Thyrocare Technologies fair value estimate is ₹540 With ₹641...New Risk • May 15New major risk - Revenue and earnings growthEarnings have declined by 1.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 0% Cash payout ratio: 147% Earnings have declined by 1.1% per year over the past 5 years.お知らせ • May 15Thyrocare Technologies Limited Proposes Final Dividend for the Financial Year 2023-24Thyrocare Technologies Limited proposed final Dividend of INR 18/- per equity share of face value of INR 10/- each for the financial year 2023-24, for approval at the ensuing Annual General Meeting.お知らせ • May 09Thyrocare Technologies Limited to Report Q4, 2024 Results on May 14, 2024Thyrocare Technologies Limited announced that they will report Q4, 2024 results on May 14, 2024分析記事 • Feb 29Getting In Cheap On Thyrocare Technologies Limited (NSE:THYROCARE) Might Be DifficultWith a price-to-earnings (or "P/E") ratio of 55.1x Thyrocare Technologies Limited ( NSE:THYROCARE ) may be sending very...お知らせ • Feb 28Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Think Health Diagnostic Private Limited.Thyrocare Technologies Limited (BSE:539871) agreed to acquire Think Health Diagnostic Private Limited for INR 3.2 million on February 1, 2024. As of March 31, 2023, Think Health Diagnostic Private Limited generated revenue of INR 7.9 million. Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Think Health Diagnostic Private Limited on February 27, 2024. Think Health has become wholly-owned subsidiary company of Thyrocare.分析記事 • Feb 04Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their ModelsThyrocare Technologies Limited ( NSE:THYROCARE ) came out with its quarterly results last week, and we wanted to see...Reported Earnings • Feb 02Third quarter 2024 earnings released: EPS: ₹2.78 (vs ₹1.89 in 3Q 2023)Third quarter 2024 results: EPS: ₹2.78 (up from ₹1.89 in 3Q 2023). Revenue: ₹1.37b (up 7.4% from 3Q 2023). Net income: ₹153.5m (up 4.3% from 3Q 2023). Profit margin: 11% (in line with 3Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.お知らせ • Jan 25Thyrocare Technologies Limited to Report Q3, 2024 Results on Feb 01, 2024Thyrocare Technologies Limited announced that they will report Q3, 2024 results on Feb 01, 2024Price Target Changed • Dec 13Price target increased by 7.3% to ₹695Up from ₹648, the current price target is an average from 2 analysts. New target price is 12% above last closing price of ₹620. Stock is up 0.8% over the past year. The company is forecast to post earnings per share of ₹15.30 for next year compared to ₹12.16 last year.分析記事 • Dec 08Here's Why Thyrocare Technologies (NSE:THYROCARE) Can Manage Its Debt ResponsiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Nov 08Why Thyrocare Technologies' (NSE:THYROCARE) Shaky Earnings Are Just The Beginning Of Its ProblemsThe subdued market reaction suggests that Thyrocare Technologies Limited's ( NSE:THYROCARE ) recent earnings didn't...Reported Earnings • Nov 02Second quarter 2024 earnings released: EPS: ₹3.84 (vs ₹3.80 in 2Q 2023)Second quarter 2024 results: EPS: ₹3.84 (up from ₹3.80 in 2Q 2023). Revenue: ₹1.48b (up 9.7% from 2Q 2023). Net income: ₹203.4m (up 32% from 2Q 2023). Profit margin: 14% (up from 11% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 22% per year.お知らせ • Oct 24Thyrocare Technologies Limited to Report Q2, 2024 Results on Oct 31, 2023Thyrocare Technologies Limited announced that they will report Q2, 2024 results on Oct 31, 2023Recent Insider Transactions • Aug 18MD, CEO & Chairman recently bought ₹4.3m worth of stockOn the 11th of August, Rahul Guha bought around 8k shares on-market at roughly ₹575 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Rahul has been a buyer over the last 12 months, purchasing a net total of ₹15m worth in shares.お知らせ • Aug 03Thyrocare Technologies Limited Appoints Alok Kumar Jagnani as Chief Financial OfficerThyrocare Technologies Limited approved the appointment of Mr. Alok Kumar Jagnani as the Chief Financial Officer ("CFO") of the Company. Date of appointment August 9, 2023. Mr. Alok Kumar Jagnani is seasoned finance professional with over 20 years of post-qualification experience in the world's manufacturing and service industries. His expertise spans across various profiles including Corporate Assurance and Risk Management, Internal Control & SOX, Retail Governance, Head of Finance, and Finance Controller for operations worth INR 30,000+ million. He also encompasses Project Finance, Business Transformation, and ERP implementation, including SAP, S4 Hana, HFM/HPM, Oracle, Readsoft, AMDOCs. He has a strong background in Merger Due Diligence, Pre and Post Merger Integration, Business and Process Transformation, Shared Service Centre Setup, and KPI Monitoring. He has also led GST (VAT) implementation projects, managing ERP/IT-related changes and communication. Prior to joining Thyrocare, he worked as Finance Controller at Greencell Group, a leading EV company, where he oversaw the end-to-end operations of the Finance department, including Accounting, MIS, FP&A, Treasury, Inventory Management. Previously he has also worked with Vodafone Idea Limited and Tata Steel Ltd.Board Change • Aug 01High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Prapti Gilada was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jul 28Thyrocare Technologies Limited to Report Q1, 2024 Results on Aug 01, 2023Thyrocare Technologies Limited announced that they will report Q1, 2024 results on Aug 01, 2023Reported Earnings • Jul 21Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: ₹12.16 (down from ₹33.30 in FY 2022). Revenue: ₹5.27b (down 11% from FY 2022). Net income: ₹643.6m (down 64% from FY 2022). Profit margin: 12% (down from 30% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) also missed analyst estimates by 32%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • Jul 15Thyrocare Technologies Limited Accepts Resignation of Sachin Salvi as Chief Financial OfficerThyrocare Technologies Limited at its board meeting held on July 14, 2023, accepted the resignation of Mr. Sachin Salvi with effect from July 31, 2023 from the post of Chief Financial Officer of the Company. Mr. Sachin Salvi has tendered his resignation from the post of Chief Financial Officer of the Company for exploring career opportunity options.Price Target Changed • Jun 12Price target decreased by 7.0% to ₹730Down from ₹785, the current price target is an average from 2 analysts. New target price is 57% above last closing price of ₹466. Stock is down 31% over the past year. The company is forecast to post earnings per share of ₹21.60 for next year compared to ₹12.16 last year.Reported Earnings • May 24Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: ₹12.16 (down from ₹33.30 in FY 2022). Revenue: ₹5.35b (down 9.1% from FY 2022). Net income: ₹644.9m (down 63% from FY 2022). Profit margin: 12% (down from 30% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) also missed analyst estimates by 32%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • May 17Thyrocare Technologies Limited to Report Q4, 2023 Results on May 23, 2023Thyrocare Technologies Limited announced that they will report Q4, 2023 results on May 23, 2023お知らせ • May 10Thyrocare Technologies Limited Announces Resignation of Vishwas Kulkarni as an Independent DirectorThyrocare Technologies Limited announced that Vishwas Kulkarni an Independent Director of the Company, has vide his letter dated May 08, 2023, tendered his resignation with effect from May 23, 2023 and requested the Board of Directors to accept his resignation.Upcoming Dividend • Apr 13Upcoming dividend of ₹18.00 per share at 3.1% yieldEligible shareholders must have bought the stock before 20 April 2023. Payment date: 07 May 2023. Payout ratio is a comfortable 56% but the company is paying out more than the cash it is generating. Trailing yield: 3.1%. Within top quartile of Indian dividend payers (1.7%). Higher than average of industry peers (0.4%).Recent Insider Transactions • Feb 12MD, CEO & Director recently bought ₹10m worth of stockOn the 6th of February, Rahul Guha bought around 20k shares on-market at roughly ₹510 per share. This transaction amounted to 80% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Rahul has been a buyer over the last 12 months, purchasing a net total of ₹26m worth in shares.Reported Earnings • Feb 05Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: EPS: ₹1.89 (down from ₹4.05 in 3Q 2022). Revenue: ₹1.28b (up 9.1% from 3Q 2022). Net income: ₹147.2m (down 32% from 3Q 2022). Profit margin: 12% (down from 18% in 3Q 2022). Revenue missed analyst estimates by 1.8%. Earnings per share (EPS) also missed analyst estimates by 43%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.お知らせ • Jan 18Thyrocare Technologies Limited to Report Q3, 2023 Results on Feb 03, 2023Thyrocare Technologies Limited announced that they will report Q3, 2023 results on Feb 03, 2023Reported Earnings • Nov 16Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: EPS: ₹3.80 (down from ₹14.70 in 2Q 2022). Revenue: ₹1.35b (down 23% from 2Q 2022). Net income: ₹154.3m (down 80% from 2Q 2022). Profit margin: 11% (down from 44% in 2Q 2022). Revenue missed analyst estimates by 8.4%. Earnings per share (EPS) also missed analyst estimates by 42%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 13Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: EPS: ₹3.80 (down from ₹14.70 in 2Q 2022). Revenue: ₹1.37b (down 23% from 2Q 2022). Net income: ₹154.3m (down 80% from 2Q 2022). Profit margin: 11% (down from 44% in 2Q 2022). Revenue missed analyst estimates by 5.7%. Earnings per share (EPS) also missed analyst estimates by 42%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.株主還元THYROCAREIN HealthcareIN 市場7D3.4%-1.4%-0.1%1Y35.3%3.0%4.8%株主還元を見る業界別リターン: THYROCARE過去 1 年間で3 % の収益を上げたIndian Healthcare業界を上回りました。リターン対市場: THYROCARE過去 1 年間で4.8 % の収益を上げたIndian市場を上回りました。価格変動Is THYROCARE's price volatile compared to industry and market?THYROCARE volatilityTHYROCARE Average Weekly Movement5.9%Healthcare Industry Average Movement5.6%Market Average Movement5.9%10% most volatile stocks in IN Market8.9%10% least volatile stocks in IN Market3.6%安定した株価: THYROCARE 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: THYROCAREの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19961,906Rahul Guhawww.thyrocare.comThyrocare Technologies Limited は、インドの患者、研究所、病院に診断検査サービスを提供している。事業セグメントは3つ：診断検査サービス、画像サービス、その他。同社は、甲状腺、成長、代謝、自己免疫、糖尿病、貧血、循環器、不妊症、各種感染症などの疾患や疾病の早期発見と管理に重点を置いた様々な医療診断検査や検査プロファイルを実施している。同社の検査プロファイルには、Aarogyamブランドで実施される検査プロファイルが含まれ、一連のウェルネス検査や予防医療検査を患者に提供している。同社はSugarscanのブランド名でグルコメーターとグルコストリップ、消耗品、放射性医薬品を販売している。Thyrocare Technologies Limitedは1996年に設立され、インドのナビ・ムンバイに拠点を置く。Thyrocare Technologies LimitedはDocon Technologies Private Limitedの子会社。もっと見るThyrocare Technologies Limited 基礎のまとめThyrocare Technologies の収益と売上を時価総額と比較するとどうか。THYROCARE 基礎統計学時価総額₹99.29b収益（TTM）₹1.76b売上高(TTM)₹8.76b56.3xPER（株価収益率11.3xP/SレシオTHYROCARE は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計THYROCARE 損益計算書（TTM）収益₹8.76b売上原価₹3.95b売上総利益₹4.82bその他の費用₹3.05b収益₹1.76b直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）11.08グロス・マージン54.96%純利益率20.12%有利子負債／自己資本比率8.6%THYROCARE の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.5%現在の配当利回り91%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/14 19:05終値2026/08/14 00:00収益2026/06/30年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Thyrocare Technologies Limited 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13 アナリスト機関null null360 ONE Capital Market Private LimitedHrishikesh Patole360 ONE Capital Market Private LimitedRahul AgarwalCGS International10 その他のアナリストを表示
分析記事 • Jul 26Thyrocare Technologies Limited Just Missed Earnings - But Analysts Have Updated Their ModelsIt's been a good week for Thyrocare Technologies Limited ( NSE:THYROCARE ) shareholders, because the company has just...
Price Target Changed • Jul 25Price target increased by 7.6% to ₹649Up from ₹603, the current price target is an average from 5 analysts. New target price is 15% above last closing price of ₹564. Stock is up 29% over the past year. The company is forecast to post earnings per share of ₹13.13 for next year compared to ₹10.24 last year.
Reported Earnings • Jul 24First quarter 2027 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2027 results: EPS: ₹3.23 (up from ₹2.45 in 1Q 2026). Revenue: ₹2.44b (up 27% from 1Q 2026). Net income: ₹521.9m (up 34% from 1Q 2026). Profit margin: 21% (up from 20% in 1Q 2026). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 5.2%. Earnings per share (EPS) missed analyst estimates by 41%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 38% per year whereas the company’s share price has increased by 43% per year.
お知らせ • Jul 16Thyrocare Technologies Limited to Report Q1, 2027 Results on Jul 23, 2026Thyrocare Technologies Limited announced that they will report Q1, 2027 results on Jul 23, 2026
お知らせ • Jul 01+ 1 more updateThyrocare Technologies Limited Approves Board Appointments, Effective May 8, 2026Thyrocare Technologies Limited at its annual general meeting held on June 30, 2026 approved the appointment of Mr. Gaurav Verma as Director (Non-Executive and Non-Independent), Mr. Uday Patel Kadam as Director (Non-Executive and Non-Independent of the Company with effect from May 8, 2026.
Upcoming Dividend • Jun 16Upcoming dividend of ₹7.00 per shareEligible shareholders must have bought the stock before 23 June 2026. Payment date: 29 July 2026. Payout ratio and cash payout ratio are on the higher end at 91% and 77% respectively. Trailing yield: 1.8%. Within top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.3%).
分析記事 • Jul 26Thyrocare Technologies Limited Just Missed Earnings - But Analysts Have Updated Their ModelsIt's been a good week for Thyrocare Technologies Limited ( NSE:THYROCARE ) shareholders, because the company has just...
Price Target Changed • Jul 25Price target increased by 7.6% to ₹649Up from ₹603, the current price target is an average from 5 analysts. New target price is 15% above last closing price of ₹564. Stock is up 29% over the past year. The company is forecast to post earnings per share of ₹13.13 for next year compared to ₹10.24 last year.
Reported Earnings • Jul 24First quarter 2027 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2027 results: EPS: ₹3.23 (up from ₹2.45 in 1Q 2026). Revenue: ₹2.44b (up 27% from 1Q 2026). Net income: ₹521.9m (up 34% from 1Q 2026). Profit margin: 21% (up from 20% in 1Q 2026). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 5.2%. Earnings per share (EPS) missed analyst estimates by 41%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 38% per year whereas the company’s share price has increased by 43% per year.
お知らせ • Jul 16Thyrocare Technologies Limited to Report Q1, 2027 Results on Jul 23, 2026Thyrocare Technologies Limited announced that they will report Q1, 2027 results on Jul 23, 2026
お知らせ • Jul 01+ 1 more updateThyrocare Technologies Limited Approves Board Appointments, Effective May 8, 2026Thyrocare Technologies Limited at its annual general meeting held on June 30, 2026 approved the appointment of Mr. Gaurav Verma as Director (Non-Executive and Non-Independent), Mr. Uday Patel Kadam as Director (Non-Executive and Non-Independent of the Company with effect from May 8, 2026.
Upcoming Dividend • Jun 16Upcoming dividend of ₹7.00 per shareEligible shareholders must have bought the stock before 23 June 2026. Payment date: 29 July 2026. Payout ratio and cash payout ratio are on the higher end at 91% and 77% respectively. Trailing yield: 1.8%. Within top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.3%).
Reported Earnings • Jun 09Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹10.27 (up from ₹5.76 in FY 2025). Revenue: ₹8.29b (up 21% from FY 2025). Net income: ₹1.63b (up 78% from FY 2025). Profit margin: 20% (up from 13% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.4%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jun 05Thyrocare Technologies Limited, Annual General Meeting, Jun 30, 2026Thyrocare Technologies Limited, Annual General Meeting, Jun 30, 2026, at 11:00 Indian Standard Time. Location: d-37/3. ttc industrial area, midc, turbhe, navi mumbai - 400703., navi mumba India
New Risk • May 14New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 91% Cash payout ratio: 116% Dividend yield: 3.0% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • May 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹471, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 40x in the Healthcare industry in India. Total returns to shareholders of 220% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹282 per share.
お知らせ • Apr 29Thyrocare Technologies Limited to Report Q4, 2026 Results on May 07, 2026Thyrocare Technologies Limited announced that they will report Q4, 2026 results on May 07, 2026
Reported Earnings • Jan 29Third quarter 2026 earnings: EPS and revenues miss analyst expectationsThird quarter 2026 results: EPS: ₹1.82 (up from ₹1.19 in 3Q 2025). Revenue: ₹1.96b (up 18% from 3Q 2025). Net income: ₹290.1m (up 52% from 3Q 2025). Profit margin: 15% (up from 12% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) also missed analyst estimates by 75%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 20Thyrocare Technologies Limited to Report Q3, 2026 Results on Jan 28, 2026Thyrocare Technologies Limited announced that they will report Q3, 2026 results on Jan 28, 2026
お知らせ • Jan 05Thyrocare Technologies Limited Appoints Rajdeep Panwar as Chief Commercial Officer, Effective January 5, 2026Thyrocare Technologies Limited approved the appointment of Mr. Rajdeep Panwar as Chief Commercial Officer of the Company, categorised as Senior Management Personnel, with effect from January 5, 2026. Mr. Rajdeep Panwar is a senior healthcare and diagnostics industry professional with over 21 years of experience, having led large-scale diagnostic networks, laboratory operations and commercial functions across reputed healthcare organisations. He most recently served as Director – GHL Pharma & Diagnostics Limited (Medanta Labs), where he led the establishment and expansion of laboratory and pharmacy business verticals across North India. His prior experience includes leadership roles at Apollo Diagnostics, Dr. Lal PathLabs, Ortho Clinical Diagnostics (Johnson & Johnson Group), Quest Diagnostics India Private Limited, Sitaram Bhartia Institute of Science & Research and Pathnet India Private Limited. Mr. Panwar has extensive experience in P&L management, laboratory network expansion, business launches, digital diagnostics initiatives, NABL/CAP accreditation, LIMS integration and large-scale team leadership, and has played a key role in scaling diagnostic operations across metro and non-metro markets. He holds an M.Sc. in Biochemistry, B.Sc. in Medical Laboratory Technology, a Diploma in Medical Laboratory Technology, and is trained as an Internal Auditor for NABL ISO 15189.
分析記事 • Dec 17Is Now The Time To Put Thyrocare Technologies (NSE:THYROCARE) On Your Watchlist?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Valuation Update With 7 Day Price Move • Nov 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹1,564, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 44x in the Healthcare industry in India. Total returns to shareholders of 173% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹818 per share.
分析記事 • Nov 17After Leaping 26% Thyrocare Technologies Limited (NSE:THYROCARE) Shares Are Not Flying Under The RadarThyrocare Technologies Limited ( NSE:THYROCARE ) shares have had a really impressive month, gaining 26% after a shaky...
Upcoming Dividend • Oct 17Upcoming dividend of ₹7.00 per shareEligible shareholders must have bought the stock before 24 October 2025. Payment date: 13 November 2025. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 1.7%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.3%).
Reported Earnings • Oct 15Second quarter 2026 earnings released: EPS: ₹9.05 (vs ₹4.99 in 2Q 2025)Second quarter 2026 results: EPS: ₹9.05 (up from ₹4.99 in 2Q 2025). Revenue: ₹2.20b (up 24% from 2Q 2025). Net income: ₹479.9m (up 80% from 2Q 2025). Profit margin: 22% (up from 15% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Oct 11Thyrocare Technologies (NSE:THYROCARE) Is Reinvesting To Multiply In ValueTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...
お知らせ • Oct 06Thyrocare Technologies Limited to Report Q2, 2026 Results on Oct 14, 2025Thyrocare Technologies Limited announced that they will report Q2, 2026 results at 12:15 PM, Indian Standard Time on Oct 14, 2025
分析記事 • Aug 23Thyrocare Technologies (NSE:THYROCARE) Has A Rock Solid Balance SheetHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Board Change • Aug 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Additional Non-Executive & Non-Independent Director Alok Jagnani was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Jul 25Thyrocare Technologies Limited's (NSE:THYROCARE) Shares Climb 40% But Its Business Is Yet to Catch UpThyrocare Technologies Limited ( NSE:THYROCARE ) shares have continued their recent momentum with a 40% gain in the...
Upcoming Dividend • Jul 18Upcoming dividend of ₹21.00 per shareEligible shareholders must have bought the stock before 25 July 2025. Payment date: 30 August 2025. The company is paying out more than 100% of its profits and is paying out 76% of its cash flow. Trailing yield: 1.8%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.3%).
お知らせ • Jul 16Thyrocare Technologies Limited to Report Q1, 2026 Results on Jul 23, 2025Thyrocare Technologies Limited announced that they will report Q1, 2026 results on Jul 23, 2025
New Risk • Jul 14New major risk - Revenue and earnings growthEarnings have declined by 8.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.3% per year over the past 5 years. Minor Risk Dividend is not well covered by earnings (122% payout ratio).
Price Target Changed • Jul 11Price target increased by 19% to ₹1,125Up from ₹943, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of ₹1,085. Stock is up 70% over the past year. The company is forecast to post earnings per share of ₹20.80 for next year compared to ₹17.28 last year.
Reported Earnings • Jul 08Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹17.13 (up from ₹13.37 in FY 2024). Revenue: ₹6.87b (up 20% from FY 2024). Net income: ₹915.1m (up 29% from FY 2024). Profit margin: 13% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 27%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.
お知らせ • Jul 07Thyrocare Technologies Limited, Annual General Meeting, Jul 31, 2025Thyrocare Technologies Limited, Annual General Meeting, Jul 31, 2025, at 10:30 Indian Standard Time. Location: d-37/3. ttc industrial area, midc, turbhe, navi mumbai - 400703., navi mumba India
分析記事 • May 02Thyrocare Technologies' (NSE:THYROCARE) Solid Earnings Have Been Accounted For ConservativelyInvestors signalled that they were pleased with Thyrocare Technologies Limited's ( NSE:THYROCARE ) most recent earnings...
分析記事 • Apr 26After Leaping 26% Thyrocare Technologies Limited (NSE:THYROCARE) Shares Are Not Flying Under The RadarThyrocare Technologies Limited ( NSE:THYROCARE ) shareholders would be excited to see that the share price has had a...
Reported Earnings • Apr 24Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹17.13 (up from ₹13.37 in FY 2024). Revenue: ₹7.02b (up 23% from FY 2024). Net income: ₹915.1m (up 29% from FY 2024). Profit margin: 13% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 27%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
お知らせ • Apr 23Thyrocare Technologies Limited Recommends Final Dividend for the Financial Year 2024-25Thyrocare Technologies Limited at its board meeting held on April 23, 2025, recommended Final Dividend of INR 21 per equity share for the financial year 2024-25 subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. The Dividend, if declared by shareholders, shall be paid within 30 days from the date of the AGM.
分析記事 • Apr 23The Returns On Capital At Thyrocare Technologies (NSE:THYROCARE) Don't Inspire ConfidenceIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
お知らせ • Apr 15Thyrocare Technologies Limited to Report Q4, 2025 Results on Apr 23, 2025Thyrocare Technologies Limited announced that they will report Q4, 2025 results on Apr 23, 2025
New Risk • Apr 08New major risk - Revenue and earnings growthEarnings have declined by 8.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.0% per year over the past 5 years. Minor Risk Dividend is not well covered by earnings (135% payout ratio).
分析記事 • Jan 28Thyrocare Technologies Limited Just Missed Earnings - But Analysts Have Updated Their ModelsThyrocare Technologies Limited ( NSE:THYROCARE ) shareholders are probably feeling a little disappointed, since its...
Reported Earnings • Jan 24Third quarter 2025 earnings: EPS misses analyst expectationsThird quarter 2025 results: EPS: ₹3.58 (up from ₹2.78 in 3Q 2024). Revenue: ₹1.70b (up 26% from 3Q 2024). Net income: ₹191.1m (up 25% from 3Q 2024). Profit margin: 11% (in line with 3Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 15%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 23Thyrocare Technologies Limited Announces Company Secretary and Compliance Officer Changes, Effect from January 31, 2025Thyrocare Technologies Limited announced that Mr. Ramjee Dorai, Company Secretary and Compliance Officer will retire from the services of the Company with effect from the close of business hours on January 31, 2025. announced the appointment of Mr. Brijesh Kumar as Company Secretary, Compliance Officer and Key Managerial Personnel of the Company with effect from January 31, 2025, to take over from Mr. Ramjee Dorai consequent on the latter's superannuation. Mr. Brijesh Kumar is a qualified Company Secretary, a law graduate, and holds an Honors degree in Commerce (B. Com Hons). He also possesses a diploma in e-Commerce and has over 12 years of experience in corporate secretarial and legal affairs. He has expertise in Securities and Capital Market Laws, Corporate Laws, FEMA, compliance management, and has handled mergers and acquisitions, share listings, fund- raising initiatives, ESOPs, joint ventures, and other critical corporate actions. Prior to joining Thyrocare Technologies Limited, he served as Head Company Secretary & Compliance Officer at Jubilant Industries Limited. Earlier he held key roles in the secretarial functions of Uno Minda Limited and AKM Global.
お知らせ • Jan 16Thyrocare Technologies Limited to Report Q3, 2025 Results on Jan 23, 2025Thyrocare Technologies Limited announced that they will report Q3, 2025 results on Jan 23, 2025
Valuation Update With 7 Day Price Move • Jan 13Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹824, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 48x in the Healthcare industry in India. Total loss to shareholders of 13% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹718 per share.
Recent Insider Transactions • Nov 07MD, CEO & Chairman recently bought ₹1.1m worth of stockOn the 1st of November, Rahul Guha bought around 1k shares on-market at roughly ₹964 per share. This transaction amounted to 2.2% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Rahul's only on-market trade for the last 12 months.
分析記事 • Oct 31Statutory Profit Doesn't Reflect How Good Thyrocare Technologies' (NSE:THYROCARE) Earnings AreThyrocare Technologies Limited ( NSE:THYROCARE ) just reported healthy earnings but the stock price didn't move much...
Price Target Changed • Oct 24Price target increased by 9.1% to ₹903Up from ₹828, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of ₹915. Stock is up 74% over the past year. The company is forecast to post earnings per share of ₹18.60 for next year compared to ₹13.37 last year.
Reported Earnings • Oct 24Second quarter 2025 earnings released: EPS: ₹4.99 (vs ₹3.84 in 2Q 2024)Second quarter 2025 results: EPS: ₹4.99 (up from ₹3.84 in 2Q 2024). Revenue: ₹1.77b (up 20% from 2Q 2024). Net income: ₹266.7m (up 31% from 2Q 2024). Profit margin: 15% (up from 14% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
Board Change • Oct 18High number of new directorsIndependent Director Nishant Shah was the last director to join the board, commencing their role in 2024.
お知らせ • Oct 16Thyrocare Technologies Limited to Report Q2, 2025 Results on Oct 23, 2024Thyrocare Technologies Limited announced that they will report Q2, 2025 results on Oct 23, 2024
Buy Or Sell Opportunity • Oct 16Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 38% to ₹890. The fair value is estimated to be ₹724, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Earnings per share has declined by 45%.
Price Target Changed • Oct 12Price target increased by 8.5% to ₹828Up from ₹763, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of ₹829. Stock is up 45% over the past year. The company is forecast to post earnings per share of ₹18.20 for next year compared to ₹13.37 last year.
お知らせ • Oct 11Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million.Thyrocare Technologies Limited (BSE:539871) entered into Business Transfer Agreement to acquire Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million on August 30, 2024. A cash consideration of INR 70 million will be paid by Thyrocare Technologies Limited. For the period ended March 31, 2024 Diagnostics and and pathological services business of Virnta Labs Limited had revenue of INR 296.67 million. Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million on October 11, 2024.
お知らせ • Sep 19+ 1 more updateThyrocare Technologies Limited Announces Cessation of Mr. Neetin Shivajirao Desai as Independent Director as Well as Member of the Respective Committee(s) of the BoardThyrocare Technologies Limited announced that the second term as Independent Director of Mr. Neetin Shivajirao Desai will be over at the close of office hours of September 19, 2024, and consequently he will cease to be a Director as well as Member of the respective Committee(s) of the Board.
Buy Or Sell Opportunity • Sep 03Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 44% to ₹869. The fair value is estimated to be ₹723, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Earnings per share has declined by 45%. Revenue is forecast to grow by 14% in a year. Earnings are forecast to grow by 35% in the next year.
お知らせ • Aug 27Thyrocare Technologies Limited Approves Dividend for the Financial Year 2023-24Thyrocare Technologies Limited at its AGM held on August 23, 2024 approved to declare dividend of INR 18 per equity share of face value of INR 10 per each for the financial year 2023-24.
お知らせ • Aug 21Thyrocare Technologies Limited Announces Cessation of Gopalkrishna Shivaram Hegde as Independent Director and as Member / Chairman of the Respective CommitteeThyrocare Technologies Limited announced that the second term as Independent Director of Mr. Gopalkrishna Shivaram Hegde will be over at the close of office hours of August 20, 2024, and consequently he will cease to be a Director as well as Member /Chairman of the respective Committee of the Board.
Buy Or Sell Opportunity • Aug 13Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 33% to ₹867. The fair value is estimated to be ₹722, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Earnings per share has declined by 45%. Revenue is forecast to grow by 14% in a year. Earnings are forecast to grow by 35% in the next year.
Upcoming Dividend • Aug 09Upcoming dividend of ₹18.00 per shareEligible shareholders must have bought the stock before 16 August 2024. Payment date: 22 September 2024. The company is paying out more than 100% of its profits and is paying out 90% of its cash flow. Trailing yield: 2.2%. Within top quartile of Indian dividend payers (1.1%). Higher than average of industry peers (0.3%).
お知らせ • Aug 02Thyrocare Technologies Limited, Annual General Meeting, Aug 23, 2024Thyrocare Technologies Limited, Annual General Meeting, Aug 23, 2024, at 16:00 Indian Standard Time. Location: d-37/3. ttc industrial area, midc, turbhe, navi mumbai - 400703., navi mumba India
分析記事 • Aug 01Thyrocare Technologies Limited (NSE:THYROCARE) Looks Just Right With A 26% Price JumpThe Thyrocare Technologies Limited ( NSE:THYROCARE ) share price has done very well over the last month, posting an...
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹776, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 45x in the Healthcare industry in India. Total loss to shareholders of 38% over the past three years.
お知らせ • Jul 30Thyrocare Technologies Limited (BSE:539871) acquired Diagnostic and pathological services business of Polo Labs Private Limited for INR 42.6 million.Thyrocare Technologies Limited (BSE:539871) entered into business transfer agreement to acquire Diagnostic and pathological services business of Polo Labs Private Limited for INR 42.6 million on July 2, 2024. The transaction is expected to complete 60 business days from the execution date of the business transfer agreement . Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostic and pathological services business of Polo Labs Private Limited on July 29, 2024.
分析記事 • Jul 26Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This YearShareholders will be ecstatic, with their stake up 20% over the past week following Thyrocare Technologies Limited 's...
Buy Or Sell Opportunity • Jul 24Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 16% to ₹765. The fair value is estimated to be ₹623, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Earnings per share has declined by 45%. Revenue is forecast to grow by 13% in a year. Earnings are forecast to grow by 35% in the next year.
Reported Earnings • Jul 24First quarter 2025 earnings released: EPS: ₹4.52 (vs ₹3.26 in 1Q 2024)First quarter 2025 results: EPS: ₹4.52 (up from ₹3.26 in 1Q 2024). Revenue: ₹1.61b (up 19% from 1Q 2024). Net income: ₹241.7m (up 40% from 1Q 2024). Profit margin: 15% (up from 13% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
お知らせ • Jul 17Thyrocare Technologies Limited to Report Q1, 2025 Results on Jul 23, 2024Thyrocare Technologies Limited announced that they will report Q1, 2025 results on Jul 23, 2024
Buy Or Sell Opportunity • Jun 12Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 3.6% to ₹662. The fair value is estimated to be ₹539, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 40%. Revenue is forecast to grow by 32% in 2 years. Earnings are forecast to grow by 58% in the next 2 years.
分析記事 • Jun 12A Look At The Fair Value Of Thyrocare Technologies Limited (NSE:THYROCARE)Key Insights Using the 2 Stage Free Cash Flow to Equity, Thyrocare Technologies fair value estimate is ₹540 With ₹641...
New Risk • May 15New major risk - Revenue and earnings growthEarnings have declined by 1.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 0% Cash payout ratio: 147% Earnings have declined by 1.1% per year over the past 5 years.
お知らせ • May 15Thyrocare Technologies Limited Proposes Final Dividend for the Financial Year 2023-24Thyrocare Technologies Limited proposed final Dividend of INR 18/- per equity share of face value of INR 10/- each for the financial year 2023-24, for approval at the ensuing Annual General Meeting.
お知らせ • May 09Thyrocare Technologies Limited to Report Q4, 2024 Results on May 14, 2024Thyrocare Technologies Limited announced that they will report Q4, 2024 results on May 14, 2024
分析記事 • Feb 29Getting In Cheap On Thyrocare Technologies Limited (NSE:THYROCARE) Might Be DifficultWith a price-to-earnings (or "P/E") ratio of 55.1x Thyrocare Technologies Limited ( NSE:THYROCARE ) may be sending very...
お知らせ • Feb 28Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Think Health Diagnostic Private Limited.Thyrocare Technologies Limited (BSE:539871) agreed to acquire Think Health Diagnostic Private Limited for INR 3.2 million on February 1, 2024. As of March 31, 2023, Think Health Diagnostic Private Limited generated revenue of INR 7.9 million. Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Think Health Diagnostic Private Limited on February 27, 2024. Think Health has become wholly-owned subsidiary company of Thyrocare.
分析記事 • Feb 04Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their ModelsThyrocare Technologies Limited ( NSE:THYROCARE ) came out with its quarterly results last week, and we wanted to see...
Reported Earnings • Feb 02Third quarter 2024 earnings released: EPS: ₹2.78 (vs ₹1.89 in 3Q 2023)Third quarter 2024 results: EPS: ₹2.78 (up from ₹1.89 in 3Q 2023). Revenue: ₹1.37b (up 7.4% from 3Q 2023). Net income: ₹153.5m (up 4.3% from 3Q 2023). Profit margin: 11% (in line with 3Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 25Thyrocare Technologies Limited to Report Q3, 2024 Results on Feb 01, 2024Thyrocare Technologies Limited announced that they will report Q3, 2024 results on Feb 01, 2024
Price Target Changed • Dec 13Price target increased by 7.3% to ₹695Up from ₹648, the current price target is an average from 2 analysts. New target price is 12% above last closing price of ₹620. Stock is up 0.8% over the past year. The company is forecast to post earnings per share of ₹15.30 for next year compared to ₹12.16 last year.
分析記事 • Dec 08Here's Why Thyrocare Technologies (NSE:THYROCARE) Can Manage Its Debt ResponsiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Nov 08Why Thyrocare Technologies' (NSE:THYROCARE) Shaky Earnings Are Just The Beginning Of Its ProblemsThe subdued market reaction suggests that Thyrocare Technologies Limited's ( NSE:THYROCARE ) recent earnings didn't...
Reported Earnings • Nov 02Second quarter 2024 earnings released: EPS: ₹3.84 (vs ₹3.80 in 2Q 2023)Second quarter 2024 results: EPS: ₹3.84 (up from ₹3.80 in 2Q 2023). Revenue: ₹1.48b (up 9.7% from 2Q 2023). Net income: ₹203.4m (up 32% from 2Q 2023). Profit margin: 14% (up from 11% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 22% per year.
お知らせ • Oct 24Thyrocare Technologies Limited to Report Q2, 2024 Results on Oct 31, 2023Thyrocare Technologies Limited announced that they will report Q2, 2024 results on Oct 31, 2023
Recent Insider Transactions • Aug 18MD, CEO & Chairman recently bought ₹4.3m worth of stockOn the 11th of August, Rahul Guha bought around 8k shares on-market at roughly ₹575 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Rahul has been a buyer over the last 12 months, purchasing a net total of ₹15m worth in shares.
お知らせ • Aug 03Thyrocare Technologies Limited Appoints Alok Kumar Jagnani as Chief Financial OfficerThyrocare Technologies Limited approved the appointment of Mr. Alok Kumar Jagnani as the Chief Financial Officer ("CFO") of the Company. Date of appointment August 9, 2023. Mr. Alok Kumar Jagnani is seasoned finance professional with over 20 years of post-qualification experience in the world's manufacturing and service industries. His expertise spans across various profiles including Corporate Assurance and Risk Management, Internal Control & SOX, Retail Governance, Head of Finance, and Finance Controller for operations worth INR 30,000+ million. He also encompasses Project Finance, Business Transformation, and ERP implementation, including SAP, S4 Hana, HFM/HPM, Oracle, Readsoft, AMDOCs. He has a strong background in Merger Due Diligence, Pre and Post Merger Integration, Business and Process Transformation, Shared Service Centre Setup, and KPI Monitoring. He has also led GST (VAT) implementation projects, managing ERP/IT-related changes and communication. Prior to joining Thyrocare, he worked as Finance Controller at Greencell Group, a leading EV company, where he oversaw the end-to-end operations of the Finance department, including Accounting, MIS, FP&A, Treasury, Inventory Management. Previously he has also worked with Vodafone Idea Limited and Tata Steel Ltd.
Board Change • Aug 01High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Prapti Gilada was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 28Thyrocare Technologies Limited to Report Q1, 2024 Results on Aug 01, 2023Thyrocare Technologies Limited announced that they will report Q1, 2024 results on Aug 01, 2023
Reported Earnings • Jul 21Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: ₹12.16 (down from ₹33.30 in FY 2022). Revenue: ₹5.27b (down 11% from FY 2022). Net income: ₹643.6m (down 64% from FY 2022). Profit margin: 12% (down from 30% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) also missed analyst estimates by 32%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • Jul 15Thyrocare Technologies Limited Accepts Resignation of Sachin Salvi as Chief Financial OfficerThyrocare Technologies Limited at its board meeting held on July 14, 2023, accepted the resignation of Mr. Sachin Salvi with effect from July 31, 2023 from the post of Chief Financial Officer of the Company. Mr. Sachin Salvi has tendered his resignation from the post of Chief Financial Officer of the Company for exploring career opportunity options.
Price Target Changed • Jun 12Price target decreased by 7.0% to ₹730Down from ₹785, the current price target is an average from 2 analysts. New target price is 57% above last closing price of ₹466. Stock is down 31% over the past year. The company is forecast to post earnings per share of ₹21.60 for next year compared to ₹12.16 last year.
Reported Earnings • May 24Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: ₹12.16 (down from ₹33.30 in FY 2022). Revenue: ₹5.35b (down 9.1% from FY 2022). Net income: ₹644.9m (down 63% from FY 2022). Profit margin: 12% (down from 30% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) also missed analyst estimates by 32%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • May 17Thyrocare Technologies Limited to Report Q4, 2023 Results on May 23, 2023Thyrocare Technologies Limited announced that they will report Q4, 2023 results on May 23, 2023
お知らせ • May 10Thyrocare Technologies Limited Announces Resignation of Vishwas Kulkarni as an Independent DirectorThyrocare Technologies Limited announced that Vishwas Kulkarni an Independent Director of the Company, has vide his letter dated May 08, 2023, tendered his resignation with effect from May 23, 2023 and requested the Board of Directors to accept his resignation.
Upcoming Dividend • Apr 13Upcoming dividend of ₹18.00 per share at 3.1% yieldEligible shareholders must have bought the stock before 20 April 2023. Payment date: 07 May 2023. Payout ratio is a comfortable 56% but the company is paying out more than the cash it is generating. Trailing yield: 3.1%. Within top quartile of Indian dividend payers (1.7%). Higher than average of industry peers (0.4%).
Recent Insider Transactions • Feb 12MD, CEO & Director recently bought ₹10m worth of stockOn the 6th of February, Rahul Guha bought around 20k shares on-market at roughly ₹510 per share. This transaction amounted to 80% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Rahul has been a buyer over the last 12 months, purchasing a net total of ₹26m worth in shares.
Reported Earnings • Feb 05Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: EPS: ₹1.89 (down from ₹4.05 in 3Q 2022). Revenue: ₹1.28b (up 9.1% from 3Q 2022). Net income: ₹147.2m (down 32% from 3Q 2022). Profit margin: 12% (down from 18% in 3Q 2022). Revenue missed analyst estimates by 1.8%. Earnings per share (EPS) also missed analyst estimates by 43%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
お知らせ • Jan 18Thyrocare Technologies Limited to Report Q3, 2023 Results on Feb 03, 2023Thyrocare Technologies Limited announced that they will report Q3, 2023 results on Feb 03, 2023
Reported Earnings • Nov 16Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: EPS: ₹3.80 (down from ₹14.70 in 2Q 2022). Revenue: ₹1.35b (down 23% from 2Q 2022). Net income: ₹154.3m (down 80% from 2Q 2022). Profit margin: 11% (down from 44% in 2Q 2022). Revenue missed analyst estimates by 8.4%. Earnings per share (EPS) also missed analyst estimates by 42%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 13Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: EPS: ₹3.80 (down from ₹14.70 in 2Q 2022). Revenue: ₹1.37b (down 23% from 2Q 2022). Net income: ₹154.3m (down 80% from 2Q 2022). Profit margin: 11% (down from 44% in 2Q 2022). Revenue missed analyst estimates by 5.7%. Earnings per share (EPS) also missed analyst estimates by 42%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare industry in India. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
